{"result": "(\"entity\"<|>EPILEPSIA<|>EVENT<|>Epilepsy is a neurological condition characterized by recurrent seizures, which is prevalent among patients with MELAS, affecting 71-96% of them.)\n##\n(\"entity\"<|>DEMENTIA<|>EVENT<|>Dementia is a cognitive decline condition that affects 40-90% of patients with MELAS, leading to memory loss and impaired reasoning.)\n##\n(\"entity\"<|>HIPOAUCIA NEUROSENSORIAL<|>EVENT<|>Sensorineural hearing loss is a condition affecting 71-77% of MELAS patients, leading to difficulties in hearing.)\n##\n(\"entity\"<|>MIOTONIA<|>EVENT<|>Myopathy is a muscular condition that is a cardinal manifestation in MELAS patients, leading to muscle weakness and intolerance to exercise.)\n##\n(\"entity\"<|>ACIDOSIS LACTICA<|>EVENT<|>Lactic acidosis is a metabolic condition that occurs in MELAS patients, affecting 94% of them, characterized by an accumulation of lactic acid in the body.)\n##\n(\"entity\"<|>MIOCARDIOPATIA NIPERTROFICA<|>EVENT<|>Hypertrophic cardiomyopathy is a cardiac manifestation affecting 18-30% of MELAS patients, leading to thickening of the heart muscle.)\n##\n(\"entity\"<|>DIABETES MELLITUS<|>EVENT<|>Diabetes Mellitus is an endocrine disorder affecting 21-33% of MELAS patients, leading to issues with blood sugar regulation.)\n##\n(\"entity\"<|>TALLA BAJA<|>EVENT<|>Short stature is a condition affecting 33-82% of MELAS patients, often due to growth hormone deficiency.)\n##\n(\"entity\"<|>HIPOTIROIDISMO<|>EVENT<|>Hypothyroidism is an endocrine disorder that can occur in MELAS patients, leading to reduced thyroid hormone levels.)\n##\n(\"entity\"<|>HIPOGONADISMO<|>EVENT<|>Hypogonadism is a condition affecting hormone production in MELAS patients, leading to reproductive issues.)\n##\n(\"entity\"<|>VOMITOS CICLICOS<|>EVENT<|>Cyclic vomiting is a digestive manifestation affecting 64-77% of MELAS patients, characterized by recurrent episodes of vomiting.)\n##\n(\"entity\"<|>DIARREA<|>EVENT<|>Diarrhea is a digestive issue that can occur in MELAS patients, leading to frequent loose or watery stools.)\n##\n(\"entity\"<|>PANCREATITIS RECURRENTE<|>EVENT<|>Recurrent pancreatitis is a digestive condition that can affect MELAS patients, leading to inflammation of the pancreas.)\n##\n(\"entity\"<|>FALLO DE MEDRO<|>EVENT<|>Failure to thrive is a condition affecting 28% of MELAS patients, characterized by inadequate growth or weight gain.)\n##\n(\"entity\"<|>ENSAYOS CLÍNICOS ALEATORIZADOS<|>EVENT<|>Randomized clinical trials are studies that have been conducted to test various treatments for MELAS, although few have been proven effective.)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: aleas recurrentes\n                                   Episodios de Stroke -like (84- 999) . Alteraciones\n                                   neurologicas focales autolimitadas y de duracion\n                                   incierta: Fundamentalmente occipitales (VISUALES):\n                                   Epilepsia (71-96%) con presentacion heterogenea:\n                                   Hipoacusia neurosensorial (71-77%) . Demencia (40-90%) .\n                                   Neuropatia periferica (22-77%).\n                                   Manifestaciones psiquiatricas:\n                                   Musculares: miopatia es la manifestacion cardinal;\n                                   intolerancia al ejercicio debilidad muscular (73-100%)\n                                  Acidosis lactica (949).\n                                   Manifestaciones cardiacas (18-30%). La mas tipica es una\n                                   miocardiopatia nipertrofica\n                                5. Endocrinas: DM (21-33%). Talla baja (33-82%) , deficiencia\n                                   de hormona de crecimiento; hipotiroidismo, hipogonadismo,\n                                   hipogonadotropo     hipoparatiroidismo.\n                                   Digestivas: Vomitos ciclicos (64-77%) . Diarrea, estrenimiento,\n                                   dismotilidad gastrica, pseudoobstruccion intestinal y\n                                   pancreatitis recurrente: Fallo de medro (28%).\n                                7 . Hematologicas_renales__pulmonares_dermatologicas\n46\n---\n         En cuanto al tratamiento específico de la enfermedad, muchos suplementos se\nhan utilizado de forma experimental, pero pocos han sido probados en ensayos clínicos\naleatorizados17 . Los estudios se centran en:\n       • Dieta cetogénica: parece reducir las crisis epilépticas en al menos la mitad de los\n       pacientes tratados sin grandes efectos adversos, pero la seguridad a largo plazo y\n       la efectividad en las enfermedades mitocondriales es desconocida. Podría ser de\n       utilidad emplear dietas que sean menos restrictivas, aunque es necesario conocer\n       el mecanismo fisiopatológico de la enfermedad en concreto18 .\n       • Arginina: su efecto terapéutico en este síndrome se presume que es debido a\n       una mejora de la biodisponibilidad de NO, llevando a aumentar la vasodilatación\n       cerebral y el flujo sanguíneo. Este mecanismo potencial se ha demostrado en ni-\n       ños y adultos en los cuales, la suplementación con arginina ha resultado en un\n       aumento de NO determinado por técnicas de infusión de isótopos19,20 . Además, se\n       ha demostrado en ensayos clínicos aleatorizados abiertos que la administración\n       intravenosa disminuye las crisis y produce una mejoría clínica. Por otro lado, la\n       arginina oral durante las fases postictales también disminuyen la frecuencia y\n       severidad de los episodios21,22 .\n       • Citrulina: los efectos clínicos de la citrulina no se han estudiado específicamen-\n       te, sin embargo, la suplementación aumenta la producción de NO en adultos y\n       niños19,20 . Curiosamente, la citrulina incrementa en mayor proporción el NO, esto\n       puede ser explicado porque amplifica la producción de arginina para que esté\n       disponible y se transforme en NO. Tanto la arginina como la citrulina, tienen pará-\n       metros farmacocinéticos similares excepto por la concentración plasmática, que\n       es mucho mayor en la citrulina, lo que hace pensar que tenga una mejor absorción\n       y biodisponibilidad que la arginina23,24 .\n       • Coenzima Q10 (CoQ10): facilita la trasferencia y estabiliza la cadena de transpor-\n       te de electrones, aportando un efecto antioxidante protector que podría tener\n       efectos beneficiosos en la debilidad muscular, la fatiga y los niveles de lactato en\n       algunos pacientes con esta enfermedad25 . CoQ10 no cruza la barrera hematoence-\n       fálica por lo que tiene un efecto limitado en el sistema nervioso central. La ide-\n       benona en un análogo del CoQ10 que puede cruzar esta barrera y ha demostrado\n       mejorar las complicaciones neurológicas en algunas series de casos26 .\n       • L-carnitina: es necesaria para la entrada de los ácidos grasos a la matriz mitocon-\n       drial donde se produce la beta oxidación. Por ello, la L-carnitina puede potencial-\n       mente mejorar la beta oxidación y reponer el pool intracelular de coenzima A17 .\n       • Creatina:    se metaboliza a fosfocreatina, un donante esencial de fosfato para\n       la regeneración de ATP en el músculo y en el cerebro, lo que mejora la fuerza\n       muscular en el ejercicio en el síndrome de MELAS27,28 .\n                                                                                              47\n---\n    Caso clínico\n             Mujer de 29 años de edad\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>MELAS<|>EVENT<|>Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) is a genetic disorder that affects multiple systems in the body, particularly the nervous system and muscles, leading to various neurological and muscular symptoms.)\n##\n(\"entity\"<|>ARGININA<|>ORGANIZATION<|>Arginine is an amino acid that is being studied for its potential therapeutic effects in treating conditions associated with MELAS, particularly in improving blood flow and reducing seizure frequency.)\n##\n(\"entity\"<|>CITRULINA<|>ORGANIZATION<|>Citrulline is an amino acid that may enhance the production of nitric oxide (NO) and is being researched for its potential benefits in patients with MELAS.)\n##\n(\"entity\"<|>COENZIMA Q10<|>ORGANIZATION<|>Coenzyme Q10 (CoQ10) is a substance that plays a critical role in energy production in cells and is being investigated for its antioxidant properties and potential benefits in treating muscle weakness and fatigue in MELAS patients.)\n##\n(\"entity\"<|>L-CARNITINA<|>ORGANIZATION<|>L-Carnitine is a nutrient that is essential for the transport of fatty acids into the mitochondria for energy production and is being studied for its potential benefits in mitochondrial diseases like MELAS.)\n##\n(\"entity\"<|>CREATINA<|>ORGANIZATION<|>Creatine is a compound that helps regenerate ATP, providing energy for muscle contractions and is being researched for its potential to improve muscle strength in MELAS patients.)\n##\n(\"entity\"<|>MUJER DE 29 AÑOS<|>PERSON<|>A 29-year-old woman who is likely a patient being discussed in a clinical case related to MELAS.)\n##\n(\"relationship\"<|>MUJER DE 29 AÑOS<|>MELAS<|>The 29-year-old woman is a patient diagnosed with MELAS, which is the focus of the clinical case.<|>8)\n##\n(\"relationship\"<|>ARGININA<|>MELAS<|>Arginine is being studied for its therapeutic effects in patients with MELAS, particularly in reducing seizure frequency and improving blood flow.<|>7)\n##\n(\"relationship\"<|>CITRULINA<|>MELAS<|>Citrulline is being researched for its potential benefits in increasing nitric oxide production in patients with MELAS.<|>6)\n##\n(\"relationship\"<|>COENZIMA Q10<|>MELAS<|>Coenzyme Q10 is being investigated for its potential antioxidant effects and benefits in treating complications associated with MELAS.<|>6)\n##\n(\"relationship\"<|>L-CARNITINA<|>MELAS<|>L-Carnitine is being studied for its potential to improve energy production in patients with MELAS.<|>6)\n##\n(\"relationship\"<|>CREATINA<|>MELAS<|>Creatine is being researched for its potential to enhance muscle strength in patients with MELAS.<|>6)\n<|COMPLETE|>"}]}